Company

Our team possesses deep, cross-functional experience and shares a longstanding commitment to developing new medicines to benefit cancer patients.

Management


ivor

Ivor Royston, M.D.

President and Chief Executive Officer

Dan-Chevallard

Dan Chevallard

Chief Operating Officer and Chief Financial Officer

Lisa-Rojkjaer

Lisa Rojkjaer, M.D.

Chief Medical Officer

Douglas-Faller

Douglas V. Faller, M.D., Ph.D.

Chief Scientific Officer

Cheryl-Madsen

Cheryl Madsen

Senior Vice President, Regulatory

Robert-McCrae

Robert McRae

Vice President, Operations and Strategic Alliances

Michael-Mueller

Michael Mueller

Vice President, Legal Affairs and General Counsel

Shelly_Vandertie

Shelly Vandertie

Vice President, Finance

Strategic Advisor


Mark A. McCamish, M.D., Ph.D.

Strategic Advisor

Board of Directors


Roger J. Pomerantz, M.D.

Chairman of the Board

Thomas E. Darcy, CPA

Director

Michael Huang, M.S., M.B.A.

Director

Sam Murphy, Ph.D.

Director

Nicole Onetto, M.D.

Director

Gur Roshwalb, M.D.

Director

Ivor Royston, M.D.

CEO, President, and Director

Stephen Rubino, Ph.D., M.B.A.

Director

Barry J. Simon, M.D.

Director

Scientific Advisory Board


Douglas V. Faller, M.D., Ph.D.

Scientific Founder and Chairman, Scientific Advisory Board

Robert Baiocchi, M.D., Ph.D.

Scientific Advisor

Corey Casper, M.D., MPH

Scientific Advisor

Charles Cobbs, M.D.

Scientific Advisor

Carl June, M.D.

Scientific Advisor

Ronald Levy, M.D.

Scientific Advisor

Pierluigi Porcu, M.D.

Scientific Advisor

Hao Shen, Ph.D.

Scientific Advisor

Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR

Scientific Advisor

Lawrence Young, Ph.D.

Scientific Advisor